BBH

VanEck Biotech ETF

TechnologyNASDAQ-GMVanEck ETF
$219.64
$-0.63 (-0.29%)
Delayed ≥20 min · Aug 13, 2026

Key Statistics

Net Assets (AUM)
$427.57M
Expense Ratio
See prospectus
Previous Close
$220.27
Day Range
$219.07 – $221.11
52-Week Range
$160.91 – $221.00
Volume
7.98K
Avg Vol (50D)
11.13K
Beta
0.68

Historical Performance

1M
+8.29%
3M
+18.09%
6M
+14.53%
YTD
+16.05%
1Y
+33.95%
3Y
+37.78%
5Y
+6.08%

Total return including reinvested distributions, from adjusted closing prices.

Price History

Price history is being compiled for this fund.

Top Holdings

Gilead Sciences Inc 14.63%
Amgen Inc 14.54%
Vertex Pharmaceuticals Inc 8.06%
Regeneron Pharmaceuticals Inc 7.51%
Argenx SE 5.28%
Insmed Inc 4.59%
IQVIA Holdings Inc 4.30%
Alnylam Pharmaceuticals Inc 4.11%
Natera Inc 3.98%
United Therapeutics Corp 3.81%
Biogen Inc 3.72%
BeOne Medicines Ltd 3.25%
Moderna Inc 3.10%
Revolution Medicines Inc 2.86%
Illumina Inc 2.49%
Incyte Corp 2.25%
BioNTech SE 2.15%
Neurocrine Biosciences Inc 1.94%
BioMarin Pharmaceutical Inc 1.39%
Bio-Techne Corp 1.35%
Charles River Laboratories International Inc 1.28%
ICON PLC 1.27%
QIAGEN NV 1.15%
Tempus AI Inc 0.93%
State Street Global Advisors 0.23%

Top 25 holdings as of Mar 31, 2026 · source: SEC N-PORT. Full holdings & prospectus →

About BBH

The Fund normally invests at least 80% of its total assets in securities that comprise the Fund’s benchmark index. For purposes of this policy, the term “assets” means net assets plus the amount of any borrowings for investment purposes. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. To be initially eligible for the Biotech Index, companies must generate at least 50% of their revenues from biotechnology. Biotechnology includes companies engaged primarily in research (including research contractors) and development as well as production, marketing and sales of drugs based on genetic analysis and diagnostic equipment (excluding pharmacies). Of the largest 50 stocks in the biotechnology industry by full market capitalization, the top 25 by free-float market capitalization (i.e., includes only shares that are readily available for trading in the market) and three month average daily trading volume are included in the Biotech Index. As of December 31, 2025, the Biotech Index included 25 securities of companies with a market capitalization range of between approximately $9.16 billion and $176.26 billion and a weighted average market capitalization of $80.47 billion. These amounts are subject to change. The Fund’s 80% investment policy is non-fundamental and may be changed without shareholder approval upon 60 days’ prior written notice to shareholders.The Fund, using a “passive” or indexing investment approach, attempts to approximate the investment performance of the Biotech Index by investing in a portfolio of securities that generally replicates the Biotech Index. Unlike many investment companies that try to “beat” the performance of a benchmark index, the Fund does not try to “beat” the Biotech Index and does not seek temporary defensive positions that are inconsistent with its investment objective of seeking to replicate the Biotech Index.The Fund is classified as a non-diversified fund under the Investment Company Act of 1940 and, therefore, may invest a greater percentage of its assets in a particular issuer. The Fund may concentrate its investments in a particular industry or group of industries to the extent that the Biotech Index concentrates in an industry or group of industries. As of September 30, 2025, each of the biotechnology and life sciences tools & services industries represented a significant portion of the Fund.

Data for BBH is aggregated from third-party providers (Tiingo, Nasdaq, Finnhub) and SEC filings, may be delayed at least 20 minutes, and may be incomplete or contain errors. Nothing here is investment advice. Verify with the official prospectus before investing.